FDA allows Alnylam to restart hemophilia treatment trials
(Reuters) - The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Bleeding | Clinical Trials | Food and Drug Administration (FDA) | Haemophilia | Health | Hemophilia